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ABSTRACT 
Emerging multidrug-resistant tuberculosis (MDR/XDR-TB) has become a major public 
health problem, placing millions at risk.  Further, nosocomial transmission of MDR/XDR-TB 
places both patients and healthcare workers at an even higher risk.  Effective tuberculosis (TB) 
infection prevention and control (IPC) policies in high-risk settings must use evidence-based 
science and should be customized to the setting.  However, the growing incidence of 
MDR/XDR-TB in some global settings raises questions about whether adequate healthcare-
related TB IPC policies are in place and whether they are implemented effectively. The purpose 
of this systematic literature review was to catalogue healthcare-related TB IPC policy research 
conducted in high-prevalence settings and draw a picture of existing evidence-based TB IPC 
policies and their implementation, with a focus on preventing and controlling nosocomial 
transmission of MDR/XDR-TB. 
Two databases (PubMed and Embase) were searched from 1990 – 2013 and outputs were 
categorized by region/country, income, MDR/XDR-TB incidence, level of IC intervention, and 
time period. None of the 20 captured research studies were conducted in TB high-prevalence, 
low-income settings.  Most (12/20) were implemented within the Pan American Health 
Organization region, followed by the African (4/20) and European (4, 20%) regions.  Most 
studies reviewed (70%) were undertaken because of an outbreak and most (70%) were published 
between 1990 – 2000.  
This systematic literature review showed a gap in research on TB IPC policies addressing 
nosocomial transmission of MDR/XDR-TB in high-prevalence, low-income settings.  TB IPC 
  
 
policy development and implementation should be routinely undertaken as a part of effective and 
efficient public health practice.  Development of TB IPC global best practices should be 
guaranteed and a concerted effort to promote, distribute, train, and implement these TB IPC best 
practices in low-resource countries would help mitigate the growing incidence of MDR/XDR-TB 
worldwide. 
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CHAPTER I: INTRODUCTION 
1.1. Overview 
Despite globally adopted strategies to control tuberculosis (TB) and globally declining 
incidence and mortality rates of the disease over the years, it remains a major public health 
problem (WHO, 2012). TB was included by Stop TB Partnership in the Millennium 
Development Goals (MDG 6) to be achieved by 191 UN Member States by the year 2015 (STOP 
TB Partnership, 2010; United Nations, 2013). The TB epidemic is complicated by the multidrug-
resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB) which is a man-made disease 
and emerged as a result of inadequate TB treatment. It is defined as “caused by organisms that 
are resistant to isoniazid and rifampicin (MDR-TB); and by organisms that are resistant to 
isoniazid and rifampicin as well as any fluoroquinolone and any of the second–line anti-TB 
injectable drugs (amikacin, kanamycin or capreomycin)” (WHO, 2013b).  Once developed, drug-
resistant strains of TB can be transmitted directly from person to person as drug-sensitive TB. 
Treatment of drug-resistant TB is expensive, long-term (18-24 months), and complex requiring 
daily injections and involving serious side effects. 
Globally MDR-TB is reported in 3.7 % of new TB cases and in 20% of previously treated 
TB, though these figures vary substantially from country to country (WHO, 2013b).  Extensively 
drug-resistant TB comprises about 9% of MDR-TB cases and has been reported in at least 84 
countries by March 2013. About 0.5 million new MDR-TB cases were estimated by WHO 
globally in 2011 with approximately 60% occurring in Brazil, Russian Federation, India, China 
and South Africa. There were 27 high MDR-TB burden countries (MDR-HBCs) estimated by 
WHO in 2008, defined as having had “at least 4000 MDR-TB cases occurring annually and/or at 
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least 10% of newly registered TB cases with MDR-TB”. The highest proportions of MDR-TB 
among TB cases, however, are in the Eastern European and Central Asian countries. High-cost 
diagnosis and long treatment of drug-resistant TB put economic burden on health systems, 
governments and other payers globally. It is estimated that two billion USD will be required in 
2015 to diagnose and treat  MDR-TB (WHO, 2013b).  Concerning is the fact that speed of 
MDR/XDR-TB propagation is much higher than slowly emerging treatment programs with less 
than 10% of the estimated cases with drug-resistant TB being treated (WHO, 2010). 
Another challenge in addressing drug-resistant TB is its interplay with HIV. People living 
with HIV (PLHIV) and infected with TB have 20 times greater risk of developing active TB than 
HIV-negative persons (WHO, 2013a). Out of 1.4 million people who died from TB in 2012, 
430,000 deaths were among PLHIV (WHO, 2012). There is evidence of significantly higher 
mortality rate and short survival associated with drug-resistant TB outbreaks among PLHIV.  
 2.2. Nosocomial Transmission  
Inadequate TB treatment regimens leading to the lower levels of success and the higher 
rates of default or failure have long been considered driving factors for drug-resistant TB. 
However, over time, dynamics of factors responsible for drug-resistant TB have changed with 
about 40% of MDR-TB patients having a history of defaulted or failed treatment, and about 30% 
of them as new cases without previous treatment history  (Figure 1)(WHO, 2011).  Furthermore, 
recent studies show even higher proportions (about 50%) of new MDR-TB cases among people 
who never been treated for TB before, demonstrating direct transmission of drug-resistant strains 
(IOM, 2011). In addition, patients, who were previously treated for TB, acquire drug-resistant 
tuberculosis through transmission rather than as a consequence of non-adherence to the previous 
treatment. When transmission happens in healthcare setting it is considered as nosocomial. 
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Figure 1.  Distribution of MDR-TB Cases by History of Previous Treatment (Source: WHO, 
2011). 
European CDC (2008) defines nosocomial infections or “healthcare-associated 
infections” (HCAI) as “infections acquired during a stay in a healthcare setting which were 
neither present nor incubating at the time of admission in a healthcare setting …including 
occupational infections among staff of healthcare facilities”. Nosocomial (healthcare-associated) 
transmission of drug-resistant TB has been documented in many countries including 
industrialized and has become a growing public health concern.  It became one of the major 
contributing factors to MDR-TB and more recently the XDR-TB epidemic which threatens 
achievements in TB control and elimination globally (WHO, 2009). Numerous outbreaks of 
nosocomial transmitted drug-resistant TB since 1990s have been associated with limited-
resource settings, high prevalence of HIV and lack of infection control policies, indicating a need 
for further and systematic examination of effective TB control strategies (Frieden TR, Sherman 
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L, Maw K, & et al, 1996); (Edlin et al., 1992); (Gandhi et al., 2013).  The Center for Global 
Development has emphasized the following causes of drug-resistant TB: health system factors, 
including infection control; drug technology; and behavioral factors (Beith, 2008) (Figure 3).  
 
Figure 2. Factors that Drive Drug-resistance (adopted from CGD, 2008).  
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Some populations are of increased risk to nosocomial transmission of drug-resistant TB 
such as patients with HIV infection and healthcare workers. HIV-positive status is related to 
higher risk of exposure to MDR-TB patients, due to increased hospitalizations in healthcare 
settings with inadequate infection control (WHO, 2010). Nosocomial transmission among 
healthcare workers (HCWs) is of particular concern because of the documented increase in rates 
of TB in this population: higher attributable risk of TB in this group compared to the general 
population (ranged from 25 to 5,361 per 100,000 per year), high prevalence of TB (on average 
54% (range 33% to 79%)), and increased risk of developing latent tuberculosis (from 0.5% to 
14.3%) (Joshi, Reingold, Menzies, & Pai, 2006).  HCWs are a valuable and often scarce 
resource, and their safety and protection from preventable TB exposure, morbidity and mortality 
should become an essential part of the IPC programs (WHO/CDC, 1999). 
 1.3.TB IPC 
Rising demand from countries for guidance on TB transmission prevention and their need 
to understand policy gaps in TB IPC led to the development of TB IPC by WHO in 2009. The 
document defined TB IPC as “a combination of measures aimed at minimizing the risk of TB 
transmission within populations...[founded on] early and rapid diagnosis and management of TB 
patients” and included evidence-based recommendations on TB infection control in healthcare 
facilities, congregate settings and households (WHO, 2009). According to WHO (2009), there is 
evidence that implementation of IPC measures, including administrative and environmental 
controls and personal protection, reduces transmission of TB in healthcare facilities (Table 1). 
Important contributing factors of nosocomial transmission as delayed diagnosis, unrecognized 
multi-drug resistance, inadequate isolation and infection control practices, poor ventilation and 
air circulation, are addressed in the WHO document. 
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Table 1. Set of measures for healthcare facility-level TB infection control (WHO, 2009)  
Facility-level measures 
 
1. Implement the set of facility level managerial activities: 
a) Identify and strengthen local coordinating bodies for TB infection control, and 
develop a facility plan (including human resources, and policies and procedures to 
ensure proper implementation of the controls listed below) for implementation. 
b) Rethink the use of available spaces and consider renovation of existing facilities or 
construction of new ones to organize implementation of controls. 
c) Conduct on-site surveillance of TB disease among health workers and asses the 
facility. 
d) Address advocacy, communication and social mobilization (ACSM) for health 
workers, patients and visitors. 
e) Monitor and evaluate the set of TB infection control measures. 
f) Participate in research efforts. 
 
Administrative controls 
 
2. Promptly identify people with TB symptoms (triage), separate infectious patients, control 
the spread of pathogens (cough etiquette and respiratory hygiene) and minimize time spent 
in healthcare facilities.  
3. Provide a package of prevention and care interventions for health workers, including HIV 
prevention, antiretroviral therapy and isoniazid preventive therapy (IPT) for HIV-positive 
health workers. 
 
Environmental controls 
 
4.  Use ventilation systems. 
5. Use ultraviolet germicidal irradiation (UVGI) fixtures, at least when adequate ventilation 
cannot be achieved. 
 
Personal protective equipment 
 
6. Use particulate respirators 
 
 
Importantly, TB IPC was neglected for many years and has been recognized as a priority 
issue that should be incorporated into country-level policy.  A majority of countries (66% of 199) 
reported having a policy on TB IPC, yet none of them had provided information on 
implementation of TB IPC measures (WHO, 2009). In 2011, less than half (41%) of the 27 
MDR-HBCs reported having the national infection control plan (WHO, 2011). 
 10 
 
 1.4. Gap and Purpose of the Study 
The growing global incidence of MDR/XDR-TB raises questions about whether adequate 
healthcare-related TB IPC policies are in place and whether they are implemented effectively. 
Continuing outbreaks of drug-resistant TB with recent high fatality XDR-TB highlight pitfalls in 
the progress of TB IPC implementation to reduce transmission of MDR and XDR TB in high 
HIV and TB burden countries (Gandhi et al., 2013).  Many questions related to TB IPC and their 
implementation in high-burden and low-income countries, still have to be answered to be able to 
effectively address nosocomial transmission of drug-resistant TB: what works effectively and 
what is feasible in certain settings in terms of resources and policies; what are the barriers for 
development and adequate implementation of TB IPC; what are the gaps and variables that are 
not understood or taken into consideration in implementing TB IPC policies?  WHO has 
recognized MDR-TB as one of “the greatest areas of unmet need for TB research”, highlighting 
urgent need to scale up research as to provide evidence to countries to reach MDG and STOP TB 
Partnership goals (WHO, 2011). 
Effective TB ICP in high-risk settings must use evidence-based science and should be 
customized to the setting. Synthesis of the current knowledge base and its distribution globally 
and in particular in the low-income MDR-HBCs might bring more understanding to the current 
challenges in control of drug-resistant TB. However, there have been a small number of 
published literature reviews on TB IPC and nosocomial transmission of MDR/XDR-TB. In 
addition, those reviews have number of limitations: available literature rarely gives global 
overview and many times analyses only one or some of the TB IPC measures, which provides a 
fragmented picture of TB IPC. Most importantly, methodology of the traditional literature review 
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carries more potential biases during selection and analysis and provides less reliable basis for 
decision making in comparison to the systematic review.  
The purpose of this systematic literature review was to catalogue healthcare-related TB 
ICP policy research conducted in high-prevalence settings and draw a picture of existing 
evidence-based TB ICP policies and their implementation, with a focus on preventing and 
controlling nosocomial transmission of MDR/XDR-TB. Studies will be categorized by region 
(WHO regions), time period (1990-2000, 2001-2013), country income level (World Bank), level 
of intervention (WHO TB IPC levels), and study settings, involvement of HIV infection and 
outbreaks. The landscape of the published TB IC research related to nosocomial drug-resistant 
TB may contribute to an understanding of the global distribution of the knowledge base and 
existing gaps. It may also inform policy makers on research and resource allocation for research 
according to the needs and resources of the regions and countries. 
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CHAPTER II. REVIEW OF THE LITERATURE 
2.1. Nosocomial transmission 
Nosocomial transmission and re-infection by MDR/XDR-TB in congregate settings has 
been investigated and documented in numerous studies as an on-going factor contributing to the 
drug-resistant TB epidemic worldwide, especially in co-variance with HIV. A recent 
observational study, exploring hospital-associated epidemiologic links in XDR- TB outbreak in 
South Africa identified nosocomial transmission links for 82% of patients (Gandhi et al., 2013). 
Almost all of the patients (93%) were hospitalized while infectious (duration M =5 days; 
interquartile range: 10–25 days). The study reported multiple generations of nosocomial 
transmission due to a high degree of interconnectedness which was facilitated by poor infection 
control measures, high HIV prevalence and delayed diagnosis. These findings have been 
supported by a number of other studies in different countries establishing nosocomial 
transmission of drug-resistant TB due to inadequate infection control measures, delayed 
diagnosis, exacerbated by HIV infection among patients and healthcare workers (Fischl et al., 
1992; Nodieva et al., 2010; Ritacco et al., 1997). Sissolak et al. (2010) has demonstrated that 
undetected cases contribute substantially to the MDR/XDR-TB pandemic due to the same 
factors, especially in high HIV-burden settings,  emphasizing inadequate infection control 
measures and potentially infectious status of those patients during their hospitalization (Sissolak, 
Bamford, & Mehtar, 2010). Another study in Japan confirms ongoing community transmission 
of MDR/XDR- TB and underlines an urgent need to improve of infection control, including an 
isolation policy for patients with drug-resistant TB (Murase et al., 2010). DNA fingerprinting 
analysis of MDR/XDR-TB strains isolated from TB patients all over Japan in 2002 showed 38% 
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of the strains arranged into 9 clusters with geographic links. Moreover, there was a significant 
association found between the XDR-TB strains and clustering in comparison to non-XDR MDR 
strains (71% vs. 24%; p = 0.003), highlighting that transmission plays a critical role in the new 
incidence of XDR TB.  
2.2. TB IPC, by levels of infection control  
A systematic review was conducted to inform development of WHO TB IPC policy and 
indicated substantial gaps in knowledge of effectiveness and efficacy of TB IPC measures 
(WHO, 2009). General findings and policy recommendations for TB IPC were elaborated by the 
document; however, it didn’t focus on IPC related to drug-resistant tuberculosis. Importantly, the 
critical need to scale up TB IPC research has been highlighted in the document. All TB IC 
recommendations in the document have specific notes on the level of recommendation and 
quality of evidence supporting it: almost all of them were indicated as strong recommendations 
with low-quality evidence.  In addition to the conventional TB IPC measures the WHO policy 
document paid special attention to some new factors, such as selective administrative controls 
(minimize time spent in health-care facilities), design of buildings, provision of HCWs with HIV 
prevention and treatment package. Finally, integration of IPC efforts with other health-system 
work, monitoring and evaluation of TB IPC and involvement of civil society on all stages of 
infection control programs, were recommended. 
According to WHO (2009), TB IPC policy with the goal to minimize the risk of 
nosocomial transmission of TB, should be a part of the national infection prevention and control 
policies (WHO, 2009). Managers on national, subnational and health facility levels are 
recommended to be directed by the developed set of four -level hierarchy infection controls with 
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administrative level as the most effective and the least expensive, followed by environmental and 
respiratory controls.  
2.2.1. Facility-level control 
Importance of the facility-level control, which includes on-site surveillance of TB among 
HCWs and assessment of the facility, was brought lately by increasing incidence of TB among 
this population.  Nosocomial TB in HCWs is suggested as “the special issue” with median 
annual incidence 5.8% (range 0%-11%) in low- income and 1.1% (range, 0.2%-12%) in high-
income countries (Shenoi, Escombe, & Friedland, 2010). Since IPC practices largely depend on 
HCWs, more behavioral research among this population is recommended by the authors. Higher 
risk for skin test conversion (25% vs 12.7%) among medical students on clinical training was 
associated with the smaller rooms, fewer windows and ineffective mechanical ventilation 
systems of healthcare settings in Lima, Peru (Nardell & Dharmadhikari, 2010). A study from 
South Africa demonstrated that HCWs in high HIV burden area were significantly more likely to 
be hospitalized with either MDR-TB or XDR-TB than were non-health care workers (O'Donnell 
et al., 2010). Incidence of MDR-TB hospitalization was estimated as 64.8 per 100,000 HCWs 
versus 11.9 per 100,000 non-HCWs (incidence rate ratio, 5.46 [95% CI, 4.75 to 6.28]). Incidence 
rate ratio of XDR-TB hospitalizations among HCWs versus non-HCWs was estimated as 6.69 
[CI, 4.38 to 10.20]). HCWs with MDR-TB or XDR-TB were more likely to be female (78% vs. 
47%; P < 0.001) and less likely to report previous tuberculosis treatment (41% vs. 92%; P < 
0.001). High occupational risk of exposure and contracting drug-resistant TB emphasizes 
importance of regular surveillance on TB among HCWs and critical need for effective TB IPC 
programs. 
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2.2.2. Administrative level controls 
Administrative level TB IPC measures aim to prevent generation of infectious droplets 
nuclei with M. tuberculosis and consequently reducing exposure of patients and HCWs to the 
infection (WHO/CDC, 1999). This level includes triage and isolation of infectious patients, 
control of the spread of M. tuberculosis through respiratory hygiene and cough etiquette, and 
reduction of time spent in hospital. Role of administrative IC level increases substantially when 
it comes to MDR-TB, which is associated with longer time of infectiousness compared to drug 
susceptible TB (Andrews, Shah, Gandhi, Moll, & Friedland, 2007). Administrative controls, in 
particular rapid diagnoses, are suggested as the most effective and least expensive interventions 
(Nardell & Dharmadhikari, 2010).  Simple triage (based on acid-fast bacilli stain (AFB) for TB 
and rapid HIV test) and separation strategy from Haiti were demonstrated as a good practice of 
administrative controls that could be tailored to resource-limited settings.  
Administrative controls should also ensure provision of prevention and care interventions 
for HCWs including HIV prevention, isoniazid preventive therapy (IPT) and antiretroviral 
therapy for HIV-positive HCWs (WHO, 2009).  HIV- infection along with other factors as 
delayed diagnosis of tuberculosis and poor infection control has been proven to increase the risk 
of transmission of multidrug-resistant strains of TB (Gandhi et al., 2013; Laing, Ocampo, & 
Harris, 2010). O’Donnell et al. compared and found in the study in South Africa differences in 
HIV infection between HCWs and non-HCWs  as not significant (55% vs. 57%), although 
comparison of HCWs to HIV-infected patients  on antiretroviral therapy (ART) was significant 
and showed HCWs as being more likely to receive ART (63% vs. 47%; P < 0.001) (O'Donnell et 
al., 2010). 
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2.2.3. Environmental level controls 
Over-crowded wards in resource-limited, high-burden settings are indicated as one of the 
main barriers to effective implementation of TB transmission control. Thus environmental 
controls are proposed to start with renovation or construction of buildings (Nardell & 
Dharmadhikari, 2010). Natural ventilation is also recommended in low-resource settings in a 
warm climate considering minimal hourly ventilation rates issued by WHO. It is recommended 
as a low cost, low maintenance and the most effective (when design of the building includes 
considerations for it) airborne infection control measure (Shenoi et al., 2010). Mechanical 
ventilation and mixed-mode systems in addition to natural ventilation are proposed by Nardell et 
al. (2010) when the latter does not sufficiently meet WHO standards.  
Germicidal ultraviolet air disinfection could be a low-cost complementary system to the 
natural and mechanical ventilation, in particular an upper room ultraviolet germicidal irradiation 
(UVGI), which is highlighted as a highly effective disinfection mean (70-80%). UVGI addresses 
limitation of natural ventilation, being climate independent, and in addition of relatively low cost 
(Shenoi et al., 2010).Yet, UVGI has its certain limitations requiring proper installation that 
depends on availability of skilled engineers, architects, and good quality and lower cost UVGI 
fixtures (Nardell & Dharmadhikari, 2010).  
2.2.4. Respiratory level controls 
WHO (2009) recommends particulate respirators for use by HCWs when caring for 
infectious or suspected in being infectious patients. For patients surgical masks are 
recommended to reduce spread of pathogens. Respiratory protection is acknowledged as a 
complementary level of protection for HCWs after other strategies have been implemented, and 
recommendations made to elaborate low-cost, non-disposable, of better appearance respirators 
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allowing verbal communication with the patients (Nardell & Dharmadhikari, 2010). Respirators 
N95 and FFFP2 have been indicated as certified and the most widely used respirators in US and 
Europe respectively. Shenoi et al. argues that even though respirators N95 were recommended as 
a personal protection, however, no discussion of the costs and availability of this type of 
protection were provided (Shenoi et al., 2010). A comprehensive training program for HCWs on 
correct and routine use of particulate respirators was recommended by WHO (2009), however, 
some studies report that fit-testing program is neglected (Nardell & Dharmadhikari, 2010). Fit-
testing for correct size and compliance to routine use of respirators were indicated as challenges 
to be addressed in personal protection.   
2.3. Implementation and compliance to the TB ICP policy 
 Literature suggests that despite availability of TB IPC policies and some of the measures 
implemented, compliance to those policies and quality of implementation may be far from being 
adequate (Humphreys, 2007). Thus regular monitoring or audit of the provision of TB IC 
measures has been recommended. Examples of low compliance and inadequate implementation 
were found in different countries, including hospitals in resource-rich settings: 122 Belgian 
hospitals in 1995 were reported to isolate only 84% of patients suspected in infectious TB and to 
have 96% of HCWs wearing masks, although masks were adequate in only 24% of rooms they 
entered; UK hospitals with only 35% out of 144 surveyed, had more than one negative-pressure 
rooms and only 27% had continuous automatic monitoring system of negative pressure of 
isolation rooms. Study in several U.S. hospitals showed that day-to-day implementation of TB 
IPC policy was not adequate with observed improper use of respirators by 65% of the HCWs and 
lack of negative pressure in 19% of patient-rooms, suggesting need in regular monitoring of the 
equipment’s performance (Sutton, Nicas, & Harrison, 2000). 
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Shenoi et al. (2010) have supported those recommendations pointing out existing gap in 
information on effectiveness and implementation of TB IPC in resource-limited high HIV and 
TB prevalence settings, and have indicated critical need to build such evidence (Shenoi et al., 
2010). More resources are needed for research and implementation of comprehensive airborne 
IPC. Murphy (2008) has suggested that there is need in re-design of the current TB IPC protocols 
in South Africa, even though the country made some progress in addressing MDR/XDR-TB 
outbreaks, to prevent further spread of the epidemics to the neighboring countries that lack 
resources and have high HIV prevalence (Murphy, 2008).  
2.4. Summary of literature review 
The literature acknowledges the main findings and recommendations made by WHO TB 
IPC policy on the following points: 
 hierarchy of the TB infection controls by levels of effectiveness 
 substantial gaps in knowledge on efficacy and effectiveness of infection controls  
 urgent need in scale up of TB IC research and its inclusion as a critical component of 
TB, HIV and overall infection control research agenda(WHO, 2009). 
Importantly, the document has underscored that rapid implementation of TB IPC policy 
based on the adequately estimated and allocated resources for all its elements would define its 
success. In addition, monitoring of the implementation of TB IPC policies would need simple 
indicators to measure progress.   
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CHAPTER III: METHODS 
This study employed a systematic review which refers to as “a review of the evidence on 
a clearly formulated question that uses systematic and explicit methods to identify, select and 
critically appraise relevant primary research, and to extract and analyze data from the studies that 
are included in the review” (Higgins JPT, 2011). Biases in selection and assessing literature for 
narrative or traditional literature reviews are not clear, thus might depend on the author’s agenda 
and competence. Moreover, literature reviews are not replicable. Systematic review, in contrast, 
identifies, assesses and synthesizes all available literature relevant to the defined question, uses 
explicit methods, is open to external scrutiny, and can be replicated and updated. Importantly, 
systematic review ensures a reliable basis for decision making. 
The author started the systematic review process with defining a research question which 
was “What is the current landscape of  healthcare-related TB IPC research conducted in high-
prevalence settings among HCWs and patients on TB ICP policies and their implementation, 
with a focus on preventing and controlling nosocomial transmission of MDR/XDR-TB?” (Table 
2). A Protocol was developed with identification of inclusion and exclusion criteria (Table 3; 
Annex1). Table 2. Research Question according to PICO  
Population Question/Intervention  Outcome  Setting 
MDR/XDR-TB 
patients (all, 
including PLHIV), 
HCWs (all, including 
PLHIV, excluding 
laboratory)  
TB infection 
control measures ( as 
defined by WHO TB 
IC policy) 
Reduced 
MDR/XDR-TB 
incidence associated 
with nosocomial 
transmission  
Healthcare 
settings: 
Any wards 
(excluding 
laboratory) 
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Key search words were developed with the support of a librarian of the public health 
school and then a search performed on two databases MEDLINE and EMBASE for published 
research papers on TB IPC interventions in the period from 1 January, 1990 to 31 August, 2013, 
based on a pre-established protocol (Table 3). The inclusion criteria was expanded to include 
mathematical modeling studies that might present interest for this research because of the lack of 
primary experimental human studies on TB infection control due to ethical issues.  Only 
publications reporting on primary studies that were peer reviewed and published in English were 
included. Grey literature as well as case reports and qualitative studies were excluded from the 
review. PUBMED database was first searched employing pre-set key search words that were 
adapted then for EMBASE database search (Table 4). There was only one reviewer (the author) 
who manually screened, identified and selected the publications based on the established criteria 
from the list of titles with abstracts generated in the databases. Full texts were screened for the 
relevant titles with missing abstracts. Duplicates were removed in two steps: first, establishing a 
command for EMBASE database to exclude records from MEDLINE, which were already 
covered by PUBMED; secondly, manually during the screening process.  
Additionally, five relevant reviews were identified and their lists of references were 
hand-searched to identify papers relevant to the research question and missing in the list of 
selected papers from the databases. Results for both databases and snowballing of the reviews 
are documented in a Flow Chart following the Cochrane standards  (Figure 3) (Higgins JPT, 
2011).  
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Table 3. Selection Criteria for Papers 
Inclusion Criteria Exclusion Criteria 
 Full text papers reporting on human 
studies in any country 
 Title and abstract (or full text when 
abstract is missing) in English; 
publications in English 
 Papers reporting on mathematical 
modeling 
 
 Case reports 
 Qualitative studies 
 Grey literature 
 Papers reporting equipment testing 
without human involvement 
 Papers related to laboratory infection 
control 
 Papers not in English 
 Papers with full texts not found  after 
search efforts 
 Reviews 
 
Data from all selected papers was extracted according to defined categories and entered 
into MS Excel database (Microsoft Corp). Categories were defined and evaluated by the author 
as levels of intervention (facility, administrative, environmental, personal), study design 
(comparative, non-comparative), setting, population (HCWs, patients), sample size, geographic 
location (WHO regional grouping applied), involvement of people living with HIV, and whether 
the studies were conducted during or after outbreaks (Table 5). Income level of the countries 
where the studies were conducted was included into categories to understand resources available 
at settings. Additional analysis of the selected articles was conducted to identify publications 
reporting on the same study and decide which papers were duplicate. This review did not intend 
to make summary of the results of the selected studies, therefore no quality assessments and 
meta-analysis were performed.  
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Table 4. Search Terms by Database, Date, Period and Number of Hits 
D
ate of 
Search 
Resource 
Used  
(database, search 
engine) 
Yea
rs Searched 
Search Terms or Strategies 
Used  
(note Limits, MeSH, etc.) 
# of 
Hits/Result
s 
8/28/2013 PubMed 1990-8/2013 ("tuberculosis, multidrug-
resistant"[MeSH Terms] OR 
("tuberculosis"[All Fields] AND 
"multidrug-resistant"[All Fields]) OR 
"multidrug-resistant tuberculosis"[All 
Fields] OR ("drug"[All Fields] AND 
"resistant"[All Fields] AND 
"tuberculosis"[All Fields]) OR "drug 
resistant tuberculosis"[All Fields]) AND 
("Cross Infection/transmission"[Mesh] 
OR "nosocomial transmission"[All 
Fields]) AND ("1990/01/01"[PDAT] : 
"2013/08/31"[PDAT]) 
119 
8/28/2013 PubMed 1990-8/2013 (drug resistant tuberculosis) AND 
"Infectious Disease Transmission, 
Patient-to-Professional"[MeSH Terms]   
58 
8/28/2013 PubMed 1990-8/2013 ("infection control"[MeSH Terms] OR 
("infection"[All Fields] AND "control"[All 
Fields]) OR "infection control"[All 
Fields]) AND ("1990/01/01"[PDAT] : 
"2013/08/31"[PDAT]) 
151 
8/28/2013 PubMed 1990-8/2013  (((drug resistant tuberculosis) AND 
(("Cross Infection/transmission"[Mesh]) 
OR "nosocomial transmission"))) OR 
((drug resistant tuberculosis) AND 
"Infectious Disease Transmission, 
Patient-to-Professional"[Mesh]) AND 
infection control 
111 
9/4/2013 EMBASE 1990-8/2013 'drug resistant tuberculosis'/exp 
OR 'drug resistant tuberculosis' 
413
8 
9/4/2013 EMBASE 1990-8/2013 nosocomial AND ('infection'/exp 
OR infection) 
266
06 
9/4/2013 EMBASE 1990-8/2013 'infection control'/exp OR 'infection 
control' 
944
15 
9/4/2013 EMBASE 1990-8/2013 ('drug resistant tuberculosis'/exp OR 
'drug resistant tuberculosis') AND 
(nosocomial AND ('infection'/exp OR 
infection) OR ('infection control'/exp OR 
204 
 23 
 
'infection control')) AND (('cross 
infection'/exp OR 'cross 
infection')OR('infection 
transmission'/exp OR 'infection 
transmission')) 
 
Table 5. Categorization Criteria of Studies 
Category Description of Category 
Study publication date Studies were categorized as published during two periods of 
time. First time period was defined as January 1990-December 
2000. Second time period was defined as January 2001-August 
2013. 
 
Study setting  Studies were categorized according to the region and country 
where the study was undertaken. Regions were defined 
according to the WHO global grouping: European, African, 
Region of Americas, Eastern Mediterranean, South-East Asia, 
and Western Pacific. In addition, countries were defined 
according to the WHO/World Bank criteria as low-income, 
lower middle income, upper middle income, and high income. 
 
Study design Studies were categorized as comparative and non-
comparative. 
Comparative studies were defined as studies comparing case-
control groups or pre-post intervention with or without 
experimental design and randomization. Non-comparative 
studies were defined as cross-sectional, descriptive, or 
mathematical modelling studies that did not compare 
interventions. 
 
Study location Study locations were categorized as routine setting, research 
setting, or mixed routine/research settings. Research setting 
was defined as setting with strong laboratory and clinical 
research facilities; setting having routine clinical and laboratory 
facilities was defined as routine;  mixed setting included 
combination of routine and mixed. 
TB infection control levels TB infection control measures involved in the studies were 
categorized by levels according to the WHO TB IC Policy (see 
Table 1): facility, administrative, environmental, and respiratory  
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CHAPTER IV. RESULTS 
There were 20 studies included for the analysis from 315 titles and abstracts screened 
from the databases and additional sources (Figure 3; Table 5). Two hundred sixty five (265) titles 
and abstracts were excluded after screening as not relevant to the research question (infection 
control and nosocomial transmission of MDR/XDR-TB) and as not meeting pre-defined study 
selection criteria. Twenty duplicate publications found as overlapping in two databases were 
removed. Full texts of the rest 30 studies selected based on the title and abstract’s relevance to 
the research question, were assessed for meeting eligibility criteria and 12 of them were excluded 
as reporting on the same study (2), irrelevant content (9) as related more to establishing 
nosocomial transmission of MDR-TB through genotyping, rather than looking into infection 
control interventions, and having no target population (1). Additional search of relevant studies 
which was performed by snowballing (handsearching) of the references of the selected five most 
relevant literature reviews, resulted in two studies that were found relevant and eligible for 
inclusion in analysis. In total, 20 studies were included in the systematic review.   
The majority of them (65%) explored TB IC among both patients and HCWs, three 
(15%) studied only patients and the remaining four (20%) only HCWs. Most the studies (70%) 
were conducted in healthcare settings during or after a drug-resistant TB outbreak, and almost 
the same proportion of the studies (75%) reported HIV infection in the populations of interest 
(Table 5).  
In terms of time, most of the studies (n=14) were published between 1992 and 2000, and 
one third of them (n=6) from 2001 to 2012. Geographically, studies were undertaken 
predominantly in the Americas region (12, 60%), Africa (4, 20%) and Europe (4, 20%). In the 
Americas region eleven studies (92%) originated from the U.S., one (8%) from Canada; all 
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studies (100%) in African region were from South Africa; reports from UK (25%), France 
(25%), Spain (25%) and one study from EU&CIS countries (25%) comprised findings from the 
European region (Figure 4). Seventy-five percent (n=15) of the studies were implemented in high 
income and low prevalence of MDR/XDR-TB countries.  
Sixteen studies (80%) addressed three and more TB IC levels of intervention; two studies 
(10%) included only personal level, another one (5%) only administrative level and the last one 
(5%) both facility and administrative levels. Proportion of investigations for each level of TB IC 
didn’t vary substantially, showing personal and administrative levels reported each in 14 studies 
(70%), environmental  and facility levels in 12 (60%) and 13 (65%) studies respectively.  
While one-third of the studies were implemented in the research settings (n=6), routine 
setting was used by most of researchers (n=12). About half of the studies were comparative. 
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Figure 3. Flow Chart for Selection of Studies on TB Infection Prevention and Control for 
Nosocomial Transmission of MDR/XDR-TB, 1990 – 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Titles and abstracts screened from PUBMED: 111  
Titles and abstracts screened from EMBASE: 204  
# of duplicates excluded -20 
 
 
# of full texts assessed for eligibility: 32 
PubMed – 24; Embase – 6;  
Identified from other sources (snowballing of 
references of 5 reviews): 2 
 
#of irrelevant titles and abstracts: 
PubMed- 87; EMBASE-178 
 
Number of full texts excluded: 12 
Reporting on the same study-2 
Irrelevant content – 9 
No target population - 1 
 
 
Number of studies included in the systematic 
review: 20  
Number of full texts unavailable: 
PubMed- 0; Embase - 0 
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Table 5. Studies Included in the Systematic Review 
# Citation Title Study year Region/ 
Country 
Study design 
(comparative/ 
noncomparat) 
1 (Farley et al., 
2012) 
A national infection control 
evaluation of drug-resistant 
tuberculosis hospitals in South 
Africa. 
 2009 African/South 
Africa 
non-
comparative 
2 (Manangan et al., 
2000) 
 
Nosocomial tuberculosis 
prevention measures among two 
groups of US hospitals, 1992 to 
1996.  
1992-1996 Americas/US comparative 
3 (Dharmadhikari et 
al., 2012) 
 
Surgical face masks worn by 
patients with multidrug-resistant 
tuberculosis: impact on 
infectivity of air on a hospital 
ward.  
2010 African/South 
Africa 
comparative 
4 (Basu et al., 2007) 
 
Prevention of nosocomial 
transmission of extensively 
drug-resistant tuberculosis in 
rural South African district 
hospitals: an epidemiological 
modelling study.  
2007-2012 African/South 
Africa 
non-
comparative 
5 (Guerrero et al., 
1997) 
 
Nosocomial transmission of 
Mycobacterium bovis resistant 
to 11 drugs in people with 
advanced HIV-1 infection. 
1993-1995 Europe/Spain non-
comparative 
6 (Boudreau et al., 
1997) 
 
Occupational risk of 
Mycobacterium tuberculosis 
infection in hospital workers. 
1989-1992 Americas/US comparative 
7 (Holton et al., 
1997) 
 
Comparison of tuberculosis 
infection control programs in 
Canadian hospitals categorized 
by size and risk of exposure to 
tuberculosis patients, 1989 to 
1993 - Part 2 
1989-1993 Americas/ 
Canada 
non-
comparative 
8 (Kenyon et al., 
1997) 
A nosocomial outbreak of 
multidrug-resistant tuberculosis. 
1994-1995 Americas/US non-
comparative. 
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9 (Jarvis, 1995) Nosocomial transmission of 
multidrug-resistant 
Mycobacterium tuberculosis. 
1989-1992 Americas/US comparative 
1 
 
(Ikeda et al., 
1995) 
 
Nosocomial tuberculosis: an 
outbreak of a strain resistant to 
seven drugs. 
1989-1992 Americas/US comparative  
1 (Stroud et al., 
1995) 
 
Evaluation of infection control 
measures in preventing the 
nosocomial transmission of 
multidrug-resistant 
Mycobacterium tuberculosis in a 
New York City hospital. 
1989-1992 Americas/US comparative  
2 (Wenger et al., 
1995) 
 
Control of nosocomial 
transmission of multidrug-
resistant Mycobacterium 
tuberculosis among healthcare 
workers and HIV-infected 
patients. 
1990-1992 Americas/US comparative 
1 (Maloney et al., 
1995) 
 
Efficacy of control 
measures in preventing 
nosocomial transmission of 
multidrug-resistant tuberculosis 
to patients and health care 
workers. 
1990-1992 Americas/US comparative  
1 (Maloney et al., 
1995) 
 
The use of high-efficiency 
particulate air-filter respirators 
to protect hospital workers from 
tuberculosis. A cost-
effectiveness analysis. 
1990-1992 Americas/US non-
comparative 
1 (Bouvet et al., 
1993)  
A nosocomial outbreak of 
multidrug-resistant 
Mycobacterium bovis among 
HIV-infected patients. A case-
control study. 
1990-1993 Europe/France non-
comparative  
1 (Beck-Sague et 
al., 1992) 
Hospital outbreak of multidrug-
resistant Mycobacterium 
tuberculosis infections. Factors 
in transmission to staff and 
HIV-infected patients. 
1988-1990 Americas/US comparative 
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1 (Sotgiu et al., 
2011) 
 
TB and M/XDR-TB infection 
control in European TB 
reference centres: The Achilles' 
heel? 
2009-2010 Europe/EU 
and CIS 
countries 
(intermediate 
and low TB 
incidence) 
non-
comparative 
1 (Basu & Galvani, 
2008) 
 
The transmission and control of 
XDR TB in South Africa: An 
operations research and 
mathematical modelling 
approach 
2006 African/South 
Africa 
non-
comparative 
1 (Fella, Rivera, 
Hale, Squires, & 
Sepkowitz, 1995) 
Dramatic decrease in tuberculin 
skin test conversion rate among 
employees at a hospital in New 
York City. 
1991-1993 Americas/US comparative  
2 (Hannan et al., 
2001) 
 
Investigation and control of a 
large outbreak of multi-drug 
resistant tuberculosis at a central 
Lisbon hospital. 
 
1996-1997 Europe/UK comparative 
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  Table 6. Results for Selected Studies          
  
      
  Appraisal n=20 
 
Country Income 
 
MDR-TB 
prevalence 
              
  
        Year of publication           
  1990-2000 14 (70%) 
      2001-2013 6 (30%) 
      
        Region           
  European Region 4 (20%) 
      African Region 4 (20%) 
      Region of the Americas 12 (60%) 
      Eastern Mediterranean Region 0 
      South-East Asia Region 0 
       Western Pacific Region 0 
            By Country           
        USA 11 (55%) 
 
high-income 
 
low-prevalence 
        Canada 1 (5%) 
 
high-income 
 
low-prevalence 
        South Africa 4 (20%) 
 
middle-income 
 
low-prevalence 
        Spain 1 (5%) 
 
high-income 
 
low-prevalence 
        EU&CIS countries 1 (5%) 
 
mixed-income  
 
mix-prevalence 
        France 1 (5%) 
 
high-income 
 
low-prevalence 
        UK 1 (5%) 
 
high-income 
 
low-prevalence 
  Study Design           
  Comparative 11 (55%) 
      Non-comparative 9 (45%) 
      TB IC by levels           
   Facility level 13   
     Administrative 14 
      Environmental 12 
      Personal 14 
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  TB IC levels  (<3 ) by study 16 (80%)         
   TB IC levels (>3 ) by study 4 (20%)         
      Personal 2 
          Facility &administr. 1 
          Administrative  1 
      Study location           
  Research setting 6 (30%) 
      Routine setting 12 (60%) 
      Mixed (research-routine) setting 1 (5%) 
      Modelling (no setting)  1 (5%) 
      Population           
  HCWs 4 (20%) 
      Patients  3 (15%) 
      Mixed 13 (65%) 
      HIV infection 15 (75%)         
  Outbreak of drug-resistant TB  14 (70%)         
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CHAPTER V. DISCUSSION 
Despite the large number of studies establishing nosocomial transmission of drug-
resistant TB among patients and HCWs and recommending improvement or introduction of TB 
IPC measures, the results of this review show a paucity of published evidence on infection 
control interventions to reduce or prevent nosocomial transmission of MDR/XDR-TB in high-
prevalence low-income settings. These findings might be of importance for the policy makers 
on global, national and subnational levels, in the context of rapidly growing incidence of drug-
resistant TB in specifically above-mentioned areas with high TB and HIV burden and low 
resources. Emerging drug-resistant TB epidemic signals on challenges and probably failures of 
the current health systems in those countries either to develop and adequately implement 
WHO’s TB ICP policies, or possibly adaptation of these policies to the local context.  Factors 
contributing to the nosocomial transmission of MDR/XDR-TB should be carefully investigated 
to understand current gaps, barriers and challenges in developing and implementing TB ICP 
policies. 
The majority of the studies were undertaken during or after outbreaks in industrialized 
countries and South Africa. Geographical concentration of studies in three regions and 
countries with low prevalence and high or middle income and lack of studies in high burden 
and low-income countries demonstrates an existing gap and critical need for further research in 
the most affected regions. Although the highest burden of the drug-resistant TB is found in 
developing countries and in certain regions (China, India, South Africa, Russian Federation, 
Ukraine, Caucasus, Central Asia), there was only one study included in the review which was 
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conducted in the European Union and CIS countries and might have covered low-income, high 
prevalence country (WHO, 2013b). This raises questions on whether the findings are due to the 
language and publication bias, and/or possible lack of expertise and resources. If the latter is 
true there is a need for increase of awareness and political commitment of policy makers to 
strengthening health systems including IPC policies and adequate practices along with the 
capacity building and resource allocation for research.  
The income level of countries seems to be related to how urgently and effectively 
nosocomial drug-resistant TB has been addressed, as well as availability of resources for 
research and development and implementation of infection control measures. For comparison, 
the estimated  percentage of MDR TB among cases in 2012 in some high-income countries 
(e.g., United States) is 1% for new cases and 2.9 % for retreatment; in UK these values are 
1.3% and 5.6% respectively; versus data from low-income high-burden countries such as 
Armenia ( 9.4% and 43%), Somalia (5.2%, 41%) and Kyrgyzstan (26%, 68%) (WHO, 2013c). 
Availability of in-country resources including technical expertise (CDC and research 
centers/universities) and funding has been critical in responding to drug-resistant TB outbreaks. 
Some studies following outbreaks in US showed that rigorous implementation of hierarchical 
TB IPC measures recommended by CDC were effective to control outbreaks; however, they 
require plentiful resources to implement those measures in a short period of time (Jensen, 
Lambert, Iademarco, & Ridzon, 2005). Experience from South Africa shows the possibility of 
collaboration with and attraction of expert teams to do research and establish evidence on 
causes of and identification of interventions that have been effective in other countries. 
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Guidelines were developed as a collaborative effort of WHO and CDC with focus on the 
resource-limited settings (WHO/CDC, 1999). 
The trend in publications over time demonstrates that the majority of studies have been 
undertaken as a response to the outbreaks, highlighting a critical need in a systematic and 
routine studies on TB IC of nosocomial transmission of drug-resistant TB in high-burden and 
low-resourced areas. Similarly, regular monitoring and evaluation of implementation of TB IC 
measures remains essential in low MDR/XDR-TB prevalence regions.  In addition, a few 
studies published in the recent years provide data on length of stay in the hospital, which has 
been identified by WHO as one of the important recommendations on reduction of time spent 
in the hospital as an administrative level measure to reduce risk of nosocomial transmission of 
drug-resistant TB.  
Most of the studies reported significant reduction of drug-resistant TB and skin test 
conversions among HCWs after implementation of three and more levels of TB IC. This 
confirms importance of comprehensive though hierarchical implementation of TB IC measures, 
with the most effective and relatively less expensive administrative level, followed by 
environmental and complimented by personal levels, as indicated in previous reviews (Nardell 
& Dharmadhikari, 2010). Effectiveness of use of personal protection interventions alone 
(respirators for HCWs, surgical masks for patients) varied across studies with some suggesting 
their effectiveness, and others reporting high cost and low effectiveness.  
Nosocomial transmission of drug-resistant TB to HCWs is indicated as a “special issue” 
by majority of the studies, supporting this observation from one of the previous reviews, with 
even higher skin test conversion rates  (Shenoi et al., 2010).  Some studies which compared 
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TST results pre and post-intervention demonstrated significant reduction of conversion after 
implementation of TB IPC measures. Other studies which compared risk of conversion of TST 
of HCWs in wards with or without exposure to drug-resistant TB patients showed varying 
results. 
Studies suggest that in order to reduce nosocomial transmission of drug-resistant TB, 
the priority and focus of TB IPC should be placed on adequate implementation of effective and 
cost-effective measures, such as administrative (triage, isolation of infectious or suspected for 
being infectious patients), adequate environmental, and respiratory (using masks) to ensure 
protection of HCWs. Importantly, implementation of those policies should be stipulated by 
context. Political commitment of the leadership on the national, subnational and facility levels 
plays crucial role in resource allocation and proper implementation of TB IPC policies. 
There is a need to implement, observe and learn about the effectiveness of TB IPC in 
addressing nosocomial transmission of MDR/XDR-TB in low-income, high-burden settings 
that are considerably different from high-income, low-burden settings where most research has 
occurred. Where the resource context differs, it seems reasonable to expect practices to differ 
also. As such, research in high-burden, low income countries could establish the effectiveness 
or (lack thereof) of current TB IPC recommendations. It is possible that such research may 
inform the establishment of new, context specific TB IPC and practice.  
It is also concerning that less than one half of the 27 MDR-TB high-burden countries 
(41%) reported having a national infection control plan (WHO, 2011). This suggests that an 
important area for future research might be in identifying and understanding the underlying 
reasons for this gap. Cross-sectional survey studies in conjunction with qualitative research cis 
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needed to assess the factors that drive decision making in these countries, specifically focused 
on why so many have neglected to implement IC policies. Another fact is that none of the 
WHO reporting countries provided information on implementation of TB ICP policies, 
including countries which report to have the policy in place. This highlights the need for further 
research aimed at better understanding the policy implementation processes and dynamics, the 
impact these policies have on practices, and the outcomes that are produced from the policies 
and corresponding practice changes.  
There is an opportunity for WHO and its technical group on infection control to 
increase and prioritize its focus on these issues, both in terms of resources and time dedicated 
to technical support to high burden, low income countries on development, implementation and 
monitoring of TB IPC policies and strategies.  Capacity building among these countries on IPC 
policies and may contribute to the effective and consistent adoption and implementation of IC 
practices with appropriate consideration of the local context (resources, culture, level of 
awareness, stigma towards TB).   
With globalization, health issues of some countries are no longer isolated. Further, they 
cross national boundaries. In the case of drug-resistant TB epidemic, success to reduce or stop 
its spread depends on the joint efforts of the global community. Efforts and resources should be 
united to address the disease locally based on evidence that should be collected in the settings 
with high TB burden, which are often low-resourced. More research on TB IPC and 
nosocomial transmission of MDR/XDR-TB should be undertaken in these countries to guide 
and inform locally feasible and effective policies and their implementation.  
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5.1. Limitations 
There were several limitations of this study. Only one person (an author) performed all 
search and selection process that could result in selection bias. However, involvement of other 
person or persons for independent selection and evaluation was not feasible, since this work 
was done as a part of a graduate program thesis. There were two major databases searched 
(PubMed, Embase), the study may benefit from more expanded search. Another limitation of 
the review might be in a language bias, as only publications in English were included, that 
excluded relevant articles published in other languages. Publication bias might lead to 
availability of more studies with positive results of the interventions that tend to be submitted 
and published rather than those with negative results. Also, because of the nature of the issue 
considered, it was not possible to conduct rigorous selection of the studies (limited only to true 
experimental studies on human subjects), which lack in this field due to ethics concern. 
5.2. Conclusion 
This systematic literature review showed a gap in research on TB IPC policies 
addressing nosocomial transmission of MDR/XDR-TB in high-prevalence, low-income 
settings.  TB IPC policy development and implementation should be routinely undertaken as a 
part of effective and efficient public health practice.  TB IPC global best practices should be 
reviewed and a concerted effort to promote, distribute, train, and implement these TB IPC 
global best practices in low-resource countries would help mitigate the growing, global 
incidence of MDR/XDR-TB. 
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